Pharma Focus Asia

Astellas Pharma Invests US$352 million (€330 million) in State-of-the-Art Facility in Kerry, Ireland

Introduction:

Astellas Pharma embarks on US$352 million (€330 million) to build a new state-of-the-art facility in Kerry, Ireland.

Features:

The state-of-the-art facility is planned to span approximately 44.7 acres in size. It will consist of a 3-storey building with a total floor area of 17,000 square metres, and the building's footprint will cover approximately 7,300 square metres. 

The primary objective of this new facility is to enhance in-house production capacity and capabilities, ensuring a consistent and reliable supply of high-quality medicines to patients worldwide. It will focus on expanding its capacity and capabilities specifically for aseptic drug products.

Furthermore, the facility aims to bolster stable production to meet the global demand for these products while also expediting the development and commercialisation of innovative antibody drugs and other new pharmaceutical products.

Construction is scheduled to commence in 2024, with the expectation that the site will become operational by 2028.

Specifications:

Name    Astellas Pharma
Type    New Construction
Budget  US$352 million (€330 Million)
Year    2028

magazine-slider-imageHexagon - Expert Insights WebinarMFA + MMA 20244th Annual Cleaning Validation 20242nd Annual Pharma Impurity Conclave 2024CPHI Korea 2024CHEMICAL INDONESIA 2024World Orphan Drug Congress Europe 2024INALAB 2024Thermo Fisher - Drug Discovery and the impact of mAbsAdvanced Therapies USA 2024ISPE Singapore Affiliate Conference & Exhibition 20242024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals Conference